Seyedkazemi Setareh, Chief Development Officer at Adverum Biotechnologies ($ADVM), made one open market sale of company shares in the last year, totaling $1,848. The most recent transaction occurred on May 15, 2025. This ranks 11,512th among 11,678 insiders by sales value, well below the average of $8.6 million and 6.4 transactions. No open market purchases recorded.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 42500 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.18% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 40000 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.17% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | U | Common Stock | 54874 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.23% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | U | Common Stock - Restricted Stock Units | 8125 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.03% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Common Stock - Performance Stock Units | 85000 | $0.00 | 88,332.0000 | 23,487,000 | 2551.02% | 0.36% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | U | Common Stock - Performance Stock Units | 88332 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.38% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 48750 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.21% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 43458 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.19% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 25000 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.11% |
| Dec. 9, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 8500 | $0.00 | 0.0000 | 23,487,000 | 100.00% | 0.04% |
| June 17, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 42500 | $0.00 | 0.0000 | 19,782,000 | 100.00% | 0.21% |
| June 17, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 42500 | $0.00 | 42,500.0000 | 19,782,000 | 9999.99% | 0.21% |
| June 17, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 8500 | $0.00 | 0.0000 | 19,782,000 | 100.00% | 0.04% |
| June 17, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 8500 | $0.00 | 8,500.0000 | 19,782,000 | 9999.99% | 0.04% |
| June 10, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | D | Stock Option (Right to Buy) | 40000 | $0.00 | 0.0000 | 19,782,000 | 100.00% | 0.20% |
| June 17, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 19,782,000 | 9999.99% | 0.20% |
| May 15, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | S | Common Stock | 924 | $2.00 | 13,768.0000 | 19,782,000 | 6.29% | 0.00% |
| Feb. 25, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 48750 | $0.00 | 48,750.0000 | 19,782,000 | 9999.99% | 0.25% |
| Feb. 25, 2025 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Common Stock | 8125 | $0.00 | 14,692.0000 | 19,782,000 | 123.72% | 0.04% |
| Aug. 2, 2024 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 43458 | $0.00 | 43,458.0000 | 20,852,000 | 9999.99% | 0.21% |
| Oct. 3, 2023 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 85000 | $0.00 | 85,000.0000 | 10,099,000 | 9999.99% | 0.84% |
| Feb. 12, 2024 | Adverum Biotechnologies, Inc. | $ADVM | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 10,082,000 | 9999.99% | 3.97% |